JP2013511728A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511728A5
JP2013511728A5 JP2012540089A JP2012540089A JP2013511728A5 JP 2013511728 A5 JP2013511728 A5 JP 2013511728A5 JP 2012540089 A JP2012540089 A JP 2012540089A JP 2012540089 A JP2012540089 A JP 2012540089A JP 2013511728 A5 JP2013511728 A5 JP 2013511728A5
Authority
JP
Japan
Prior art keywords
antigen
subject
antibody
stage
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511728A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057427 external-priority patent/WO2011063232A1/en
Publication of JP2013511728A publication Critical patent/JP2013511728A/ja
Publication of JP2013511728A5 publication Critical patent/JP2013511728A5/ja
Pending legal-status Critical Current

Links

JP2012540089A 2009-11-20 2010-11-19 癌のバイオマーカー Pending JP2013511728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26323509P 2009-11-20 2009-11-20
US61/263,235 2009-11-20
PCT/US2010/057427 WO2011063232A1 (en) 2009-11-20 2010-11-19 Biomarkers of cancer

Publications (2)

Publication Number Publication Date
JP2013511728A JP2013511728A (ja) 2013-04-04
JP2013511728A5 true JP2013511728A5 (cg-RX-API-DMAC7.html) 2014-01-16

Family

ID=44060024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540089A Pending JP2013511728A (ja) 2009-11-20 2010-11-19 癌のバイオマーカー

Country Status (6)

Country Link
US (1) US20150005187A1 (cg-RX-API-DMAC7.html)
EP (1) EP2501845A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013511728A (cg-RX-API-DMAC7.html)
AU (1) AU2010321787B2 (cg-RX-API-DMAC7.html)
CA (1) CA2781408A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011063232A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102393458B (zh) * 2011-08-24 2013-12-18 绍兴市人民医院 一种早期乳腺癌血清诊断试剂
US20140186293A1 (en) * 2012-12-31 2014-07-03 University Of Louisville Research Foundation, Inc. Immunoglobulin-bound extracellular vesicles and uses thereof
EP2951592A4 (en) * 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer
EP3281016A1 (en) * 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2022076237A1 (en) * 2020-10-05 2022-04-14 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780161B1 (fr) 1998-06-17 2000-09-29 Centre Nat Rech Scient Procede de diagnostic precoce du cancer base sur la recherche d'auto-anticorps diriges contre la proteine csk et trousse pour sa mise en oeuvre
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US20030119079A1 (en) 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US20030109464A1 (en) * 2001-09-28 2003-06-12 Huflejt Margaret E. Galectins -1 and -4 in tumor development
US20050158737A1 (en) * 2002-03-27 2005-07-21 Alison Banham Tumour associated antigens
GB0412301D0 (en) * 2004-06-02 2004-07-07 Diagenic As Product and method
JP2007322211A (ja) * 2006-05-31 2007-12-13 Green Peptide Co Ltd がん患者の予後予測方法
EP2450702A3 (en) * 2007-01-26 2012-07-25 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer

Similar Documents

Publication Publication Date Title
Lin et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer
US20200048353A1 (en) Anti-b7-h3 antibodies and diagnostic uses thereof
JP2015533788A5 (cg-RX-API-DMAC7.html)
Steenholdt et al. Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease
WO2001020333A1 (en) Early cancer tumor marker
JP2008530582A5 (cg-RX-API-DMAC7.html)
RU2016109642A (ru) Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1
RU2769987C2 (ru) Анализ антител
CN103518135B (zh) 冠状动脉疾病的生物标志物
JP2013511728A5 (cg-RX-API-DMAC7.html)
JP2020510409A5 (cg-RX-API-DMAC7.html)
Perez Alamino et al. The great mimicker: IgG4-related disease
KR101951514B1 (ko) 전립선암 분석을 위한 조성물 및 방법
ES2967740T3 (es) GDF-15 como marcador de diagnóstico de melanoma
JP6991968B2 (ja) 抗ヒトヘモグロビンモノクローナル抗体若しくは抗体キット、抗ヒトヘモグロビンモノクローナル抗体固定化不溶性担体粒子、及びこれらを用いた測定試薬若しくは測定方法
JP7315968B2 (ja) 生物学的試料中の遊離aimの免疫学的分析方法及び対象におけるnashの検出方法
EP3094973A1 (en) Biomarkers
Kazuno et al. Multi-sequential surface plasmon resonance analysis of haptoglobin–lectin complex in sera of patients with malignant and benign prostate diseases
JP2018515761A (ja) 腎疾患の検出方法
CN103842823A (zh) 用于胸膜间皮瘤患者的早期发现的分子标志物及其表达分析方法
Beneduce et al. Tumour‐specific induction of immune complexes: DCP‐IgM in hepatocellular carcinoma
US10001492B2 (en) Method for diagnosing inflammatory bowel disease
JPWO2009147999A1 (ja) IgA腎症の検査方法及び検査キット
CN110687284B (zh) 检测血清中six2自身抗体的试剂的应用
JP7315965B2 (ja) ウィルス性肝癌の検出方法